NASDAQ · Medical Devices · USD
Treace Medical Concepts, Inc. (TMCI) Stock Analysis
Treace Medical Concepts, Inc. (TMCI) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TMCI Key Statistics
As of Sep 4, 2026Trading
- Open
- $4.82
- Previous Close
- $4.88
- Day's Range
- 4.72–4.89
- 52-Week Range
- 1.17–7.63
- Volume
- 231.80K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.41
Valuation
- Market Cap
- $312.82M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 1.52
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.92
Financials (FY)
- Revenue (FY)
- $212.69M+1.59%
- Net Income (FY)
- −$59.00M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −28.99%
- Shares Outstanding
- 65.03M
- 1-Year Return
- −32.91%
Dividend and dates
- Earnings Date
- November 5, 2026
- Avg Volume
- 648.76K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
TMCI Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +96.33% |
| 2025 | −67.07% |
| 2024 | −41.65% |
| 2023 | −44.54% |
| 2022 | +23.34% |
| 2021 (partial year) | −26.99% |
As of September 4, 2026.
TMCI Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $212.69M | −$59.00M | −27.7% |
| 2024 | $209.36M | −$55.74M | −26.6% |
| 2023 | $187.12M | −$49.53M | −26.5% |
| 2022 | $141.84M | −$42.82M | −30.2% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $212.69M | $169.75M | −$54.15M | −$59.00M | −27.7% |
| 2024 | $209.36M | $168.26M | −$55.69M | −$55.74M | −26.6% |
| 2023 | $187.12M | $151.94M | −$51.43M | −$49.53M | −26.5% |
| 2022 | $141.84M | $116.31M | −$34.84M | −$42.82M | −30.2% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
TMCI Valuation vs Medical Devices Median
Median of 151 stocks| Metric | TMCI | Medical Devices median | vs median |
|---|---|---|---|
| P/S ratio | 1.52 | 2.98 | 49% below |
| Profit margin | −28.99% | −1.69% | 27.3 pts below |
Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $5
BenzingaTreace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
SeekingAlphaTreace Medical Concepts (NASDAQ:TMCI) Rises as Q2 Loss Narrows, Revenue Matches Estimates
ChartMillTreace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate
BenzingaTreace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Medical Devices Stocks
Abbott Laboratories
$187.45B
MDTMedtronic plc.
$120.46B
SYKStryker Corporation
$116.27B
BSXBoston Scientific Corporation
$69.27B
EWEdwards Lifesciences Corporation
$51.82B
DXCMDexCom, Inc.
$33.17B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B